Cargando…

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection

We experienced two patients with serious arrhythmias associated with the administration of ledipasvir (LDV) and sofosbuvir (SOF). Neither patient took amiodarone, an agent for which concomitant use is prohibited. One patient was 82 years old and hypertensive; the other was 72 years old and had no ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nirei, Kazushige, Nakamura, Hitomi, Matsuoka, Shunichi, Yamana, Yoichiro, Yoda, Shunichi, Hirayama, Atsushi, Moriyama, Mitsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457921/ https://www.ncbi.nlm.nih.gov/pubmed/28381744 http://dx.doi.org/10.2169/internalmedicine.56.7948

Ejemplares similares

Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2018)

Portal-systemic Encephalopathy due to Complicated Spleno-renal Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration Using a Double Coaxial Balloon Catheter System and Shape-memory Coils
por: Matsuoka, Shunichi, et al.
Publicado: (2018)

Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients
por: Mizutani, Taku, et al.
Publicado: (2022)

Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients
por: Nirei, Kazushige, et al.
Publicado: (2017)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Expression of Intercellular Adhesion Molecule-1 in the Livers of Rats Treated with Diethylnitrosamine
por: Matsuoka, Shunichi, et al.
Publicado: (2009)

Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir
por: Totsuka, Mai, et al.
Publicado: (2021)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
por: Yamana, Yoichiro, et al.
Publicado: (2021)

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
por: Ogbuagu, Onyema, et al.
Publicado: (2018)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
por: Lee, Soon Kyu, et al.
Publicado: (2022)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Real World Experience of Sofosbuvir/Ledipasvir Therapy in HIV Patients Co-infected with HCV: A Retrospective Study
por: Al Obaidi, Mohanad, et al.
Publicado: (2017)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
por: Alcazer, Vincent, et al.
Publicado: (2018)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
por: Marascio, Nadia, et al.
Publicado: (2019)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
por: Do, Albert, et al.
Publicado: (2015)

Zinc Supplementation Improves the Outcome of Chronic Hepatitis C and Liver Cirrhosis
por: Matsuoka, Shunichi, et al.
Publicado: (2009)

Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis
por: Khan, Mohammad Qasim, et al.
Publicado: (2017)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Involvement of Ornithine Carbamoyltransferase in the Progression of Chronic Hepatitis C and Liver Cirrhosis
por: Ohnishi, Masahiko, et al.
Publicado: (2017)

Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease
por: Ogawa, Masahiro, et al.
Publicado: (2019)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
por: Omotani, Sachiko, et al.
Publicado: (2020)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
por: Wei, Lai, et al.
Publicado: (2018)

Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis
por: Tucci, Francesca, et al.
Publicado: (2018)

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
por: Liou, Bo-Huang, et al.
Publicado: (2021)

Apoptosis and non-alcoholic fatty liver diseases
por: Kanda, Tatsuo, et al.
Publicado: (2018)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram, Vinay, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r1529ost1jmmqfmu74qcitc8m9